“With bold investments in industry-leading technology platform companies, Bayer has bolstered its R&D capabilities and strengthened its early development pipeline”, Stefan Oelrich, member of the Bayer AG board of management and president of its pharmaceuticals division, said at the Bayer’s annual Pharma Media Day